on Biotest AG (isin : DE0005227201)
Biotest Submits Fibrinogen Application to FDA

Biotest AG has reached a significant milestone by submitting a Biologics License Application for its Fibrinogen to the US Food and Drug Administration (FDA). This product aims to address the unmet medical need for treating acquired fibrinogen deficiency. The application also extends to the treatment and prevention of acute bleeding in patients with congenital fibrinogen deficiency. A decision from the FDA is expected by the end of 2025.
This submission follows Biotest's marketing authorization application in Europe in October 2024. Fibrinogen offers advantages over current treatments, such as cryoprecipitate or fresh frozen plasma, by providing high-purity fibrinogen and faster preparation time. Biotest, a member of the Grifols Group, is focused on broadening patient access to this therapy.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biotest AG news